Brainstorm announces high-level fda feedback on nurown® als clinical development program

New york, feb. 22, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the u.s. food and drug administration (fda) and...

BCLI Ratings Summary

BCLI Quant Ranking